Our top pick for
Building a portfolio
DocuSign, Inc is a software-application business based in the US. DocuSign shares (DOCU) are listed on the NASDAQ and all prices are listed in US Dollars. DocuSign employs 5,630 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$233.24|
|52-week range||$179.49 - $286.51|
|50-day moving average||$230.48|
|200-day moving average||$228.57|
|Wall St. target price||$276.17|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.37|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-06-26)||N/A|
|1 month (2021-06-07)||-3.21%|
|3 months (2021-04-07)||13.38%|
|6 months (2021-01-07)||-2.42%|
|1 year (2020-07-07)||17.95%|
|2 years (2019-07-05)||347.16%|
|3 years (2018-07-06)||324.46%|
|5 years (2016-07-03)||N/A|
Valuing DocuSign stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of DocuSign's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
DocuSign's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 3.9419. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into DocuSign's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
|Revenue TTM||$1.6 billion|
|Gross profit TTM||$1.1 billion|
|Return on assets TTM||-4.23%|
|Return on equity TTM||-53.21%|
|Market capitalisation||$54.1 billion|
TTM: trailing 12 months
There are currently 7.8 million DocuSign shares held short by investors – that's known as DocuSign's "short interest". This figure is 38.9% up from 5.6 million last month.
There are a few different ways that this level of interest in shorting DocuSign shares can be evaluated.
DocuSign's "short interest ratio" (SIR) is the quantity of DocuSign shares currently shorted divided by the average quantity of DocuSign shares traded daily (recently around 3.7 million). DocuSign's SIR currently stands at 2.12. In other words for every 100,000 DocuSign shares traded daily on the market, roughly 2120 shares are currently held short.
However DocuSign's short interest can also be evaluated against the total number of DocuSign shares, or, against the total number of tradable DocuSign shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case DocuSign's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 DocuSign shares in existence, roughly 40 shares are currently held short) or 0.0409% of the tradable shares (for every 100,000 tradable DocuSign shares, roughly 41 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against DocuSign.
Find out more about how you can short DocuSign stock.
We're not expecting DocuSign to pay a dividend over the next 12 months.
Over the last 12 months, DocuSign's shares have ranged in value from as little as $179.49 up to $286.51. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while DocuSign's is 0.8174. This would suggest that DocuSign's shares are less volatile than average (for this exchange).
DocuSign, Inc. provides cloud based software in the United States and internationally. The company provides e-signature solution that enables businesses to digitally prepare, sign, act on, and manage agreements. It also offers CLM, which automates workflows across the entire agreement process; Insights that use artificial intelligence (AI) to search and analyze agreements by legal concepts and clauses; Gen for Salesforce, which allows sales representatives to automatically generate agreements with a few clicks from within Salesforce; Negotiate for Salesforce that supports for approvals, document comparisons, and version control; Analyzer, which helps customers understand what they're signing before they sign it; and CLM+ that provide AI-driven contract lifecycle management. The company provides Guided Forms, which enable complex forms to be filled via an interactive and step-by-step process; Click that supports no-signature-required agreements for standard terms and consents; Identify, a signer-identification option for checking government-issued IDs; Standards-Based Signatures, which support signatures that involve digital certificates; Payments that enables customers to collect signatures and payment; and eNotary, which offers the ability to execute electronic notarial acts. It offers industry-specific cloud offerings, including Rooms for Real Estate that provides a way for brokers and agents to manage the entire real estate transaction digitally; Rooms for Mortgage, which offers digital workspace to create and close mortgages; FedRAMP, an authorized version of DocuSign eSignature for U. S.
Everything we know about the Huake Holding Biology Co IPO, plus information on how to buy in.
Everything we know about the Outbrain IPO, plus information on how to buy in.
Everything we know about the Duolingo IPO, plus information on how to buy in.
Everything we know about the Elicio Therapeutics IPO, plus information on how to buy in.
Everything we know about the Paltalk IPO, plus information on how to buy in.
Everything we know about the Instructure Holdings IPO, plus information on how to buy in.
Everything we know about the Ipsidy IPO, plus information on how to buy in.
Everything we know about the ScoutCam IPO, plus information on how to buy in.
Everything we know about the Candel Therapeutics IPO, plus information on how to buy in.
Everything we know about the Xponential Fitness IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.